Eisele Jeffrey's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Dec 28, 2023
- Accession no.
- 0001127602-23-030552
- Filed
- Dec 28, 2023
- Trade date
- Dec 26-27, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $18.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Eisele JeffreyCIK 0001827326 | Officer (Chief Development Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 26, 2023 | Common Stock | SSaleDisposed | −68 | $57.86 | −$3,934.48 | 53,815 | Direct | |
| Dec 27, 2023 | Common Stock | SSaleDisposed | −235 | $60.23 | −$14,154.05 | 53,580 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.